Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Glioblastoma 1Genomic Instability 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Adenocarcinoma of Lung 1ALK-positive NSCLC 1ALK+ Advanced NSCLC 1ALK Gene Rearrangement Positive 1

Interventions

Gemcitabine 35Cisplatin 21Capecitabine 17Oxaliplatin 16Leucovorin 11Fluorouracil 11pembrolizumab 8S 1 (combination) 8Nivolumab 6tremelimumab 5durvalumab 5Bevacizumab 5lenvatinib 4Irinotecan 4trametinib 3titanium silicide 3atezolizumab 3Radiofrequency Ablation 3zanidatamab 2vandetanib 2irinotecan sucrosofate 2derazantinib 2camrelizumab 2binimetinib 2apatinib 2Trastuzumab 2Tegafur 2Radiotherapy 2Panitumumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Biliary Tract Neoplasms × alectinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡